日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Experts stress reform of pharmaceutical sector

By LIU ZHIHUA | China Daily | Updated: 2021-08-28 09:29
Share
Share - WeChat
China's pharmaceutical companies need to align themselves with the national goal of high-quality development by improving the quality of drugs and optimizing their management and cost control methods. [Photo/IC]

China's pharmaceutical companies need to align themselves with the national goal of high-quality development by improving the quality of drugs and optimizing their management and cost control methods, industry experts said.

That is an inherent requirement of the ongoing reform of the drug regulations and the healthcare system.

The reform aims at encouraging genuine innovation to enhance the quality of healthcare products and services while lowering the costs of disease treatment, they said.

They made their comments after Shanghai-listed North China Pharmaceutical became the first company to be banned this week for nine months from China's centralized drugs procurement program, after it breached a contract to supply ibuprofen sustained release capsules to Shandong province.

China launched the national volume-based drug procurement mechanism in late 2018, which requires drugmakers to significantly cut prices to win bids for enrollment in large-volume procurement led by the government.

The company won the contract in a third-round bulk-buying bid about a year ago to provide the medicine for seven provinces and cities for three years. But, it stopped supplies to Shandong recently, and blamed the lack of capacity due to COVID-19 disruption and improper internal management.

The nation's centralized drug procurement office then decided to ban the company from the program for nine months until next May.

The authorities concerned also said they will take more punitive measures against the company if it fails to honor the supply obligation for other regions.

Ju Zhao, deputy director of research of market consultancy iResearch, said: "The Chinese authorities are determined to solve problems like unreasonably high sales costs and drug prices in the healthcare sector, to lower treatment costs for the public. That's of great importance for improving people's lives and is going to reshape the sector."

Most tender winners in the national bulk-buying bidding process are earnestly implementing the contracts, and the action against North China Pharmaceutical has shown the authorities' attitude toward breach of contracts, Ju said.

China has conducted bulk-buying bids five times so far. Data from the nation's centralized drug procurement office showed winners of the first three bids have supplied much more than the contracted drug amount.

The office also said drug prices are unreasonably high in China, as many common drugs are priced two to three times that in other key economies, while sales expenses of mainstream pharmaceutical companies account for nearly 40 percent of their sales revenues, posing a significant burden to the nation's public medical insurance fund and hindering healthy growth of the healthcare industry.

Among the four enterprises that won the bids to supply ibuprofen sustained release capsules, North China Pharmaceutical won a contract in spite of quoting the highest price, which was also close to the price at which it had sold the capsules in some other provinces and cities.

Before centralized bulk-buying of drugs, North China Pharma's sales revenue from the pills was only about 500,000 yuan ($77,168) in 2020, the office said, adding winning the bulk-supply bid would have ensured annual sales of over 20 million yuan.

Honoring the agreement is the foundation of a market economy, and it is a bid winners' obligation to fulfill an agreement based on the agreed prices, according to the office.

According to Shi Lichen, founder of medical consulting firm Beijing Dingchen Consultancy, Chinese pharmaceutical enterprises must become innovative, upgrade their sales approach, optimize their product portfolio and operations, and pay more attention to non-hospital drug buyers, to nurture competitiveness as the centralized drug procurement is expected to cover more drug titles in the future.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 波多野结衣一区二区三区在线观看 | 久久草在线视频观看 | 99国产精品视频免费观看 | 亚洲综合色丁香婷婷六月图片 | 日韩欧美一级大片 | 欧美两性网 | 久操久操| 亚洲视频在线一区二区 | 亚洲一区久欠无码A片 | 国产成人一级 | 国产一级毛片在线看 | 亚洲综合亚洲 | 就草草在线观看视频 | 排球少年第五季樱花动漫免费观看 | 羞羞视频网站在线看 | 精品一区二区三区免费看 | 91香蕉视频在线看 | 97成人在线视频 | 中文字幕成人av | 日本免费不卡一区二区 | 精品黄网| 99成人精品视频 | 久久亚洲国产精品五月天婷 | 午夜影院在线视频 | 欧美色偷偷亚洲天堂bt | 九九久久精品 | 欧洲精品欧美精品 | 亚洲综合图片色婷婷另类小说 | 日本不卡在线一区二区三区视频 | 贺鹏个人资料 | 中国一级特黄真人毛片免费看 | 美国黄色毛片 | 国产视频大全 | 国产精品极品美女在线观看免费 | 99热官网 | 国产精品国产三级国产aⅴ中文 | 国产一区久久久 | 夜夜夜夜爽| 99免费| 一区二区三区免费在线观看 | 成人久久久 |